Fubotv earnings beat by $0.10, revenue topped estimates
Director Leslie W. Kreis, along with entities he is affiliated with, reported purchasing 71,428 shares of Actuate Therapeutics , Inc. (NASDAQ:ACTU) common stock at a price of $7.0 per share, for a total transaction value of $499,996. The transaction occurred on June 27, 2025. The purchase comes as the stock has declined over 15% in the past week, with shares currently trading at $6.2. According to InvestingPro, analysts maintain ambitious price targets ranging from $20 to $35 for this $117 million market cap company.
The purchase was made by Bios 2024 Co-Invest, LP. In addition, Bios 2024 Co-Invest, LP purchased warrants to purchase 71,428 shares of Common Stock. Kreis is affiliated with Bios Equity Partners, LP, which is the general partner of several entities holding Actuate Therapeutics stock. He also has voting and investment control with respect to shares held indirectly by Cavu Advisors, LLC. InvestingPro analysis indicates the company’s overall financial health score is currently weak, with several key metrics available to subscribers.
In other recent news, Actuate Therapeutics has announced that its drug elraglusib, in combination with chemotherapy, has met primary endpoints in a Phase 2 trial for treating metastatic pancreatic ductal adenocarcinoma. The study demonstrated a statistically significant improvement in overall survival for patients treated with this combination compared to those receiving chemotherapy alone. Additionally, the company identified seven biomarkers that may help predict which patients could benefit from elraglusib, with elevated levels of CXCL2 being associated with improved survival outcomes. These findings were presented at the American Society of Clinical Oncology annual meeting. Craig-Hallum has initiated coverage on Actuate Therapeutics with a Buy rating and a price target of $21.00, citing optimism about elraglusib’s potential to improve survival outcomes in first-line metastatic pancreatic ductal adenocarcinoma. The analysts expect the interim data to continue showing a meaningful difference in median overall survival when compared to standard care. Actuate plans to engage with U.S. and EU regulators later this year to discuss advancing the drug toward a New Drug Application. The company’s financial position, with $8.6 million in cash at the end of the previous year, could be bolstered by these positive developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.